美股市场个股详情
ATAI ATAI Life Sciences
- 1.190
- 0.0000.00%
收盘价 12/20 16:00 (美东)
- 1.230
- +0.040+3.37%
盘后 20:01 (美东)
2.00亿总市值-1.49市盈率TTM
1.260最高价1.150最低价246.23万股成交量1.190今开1.190昨收297.35万成交额1.91%换手率亏损市盈率(静)1.68亿总股本2.85052周最高1.37市净率1.53亿流通值1.03052周最低--股息TTM1.29亿流通股22.910历史最高--股息率TTM9.24%振幅1.025历史最低1.207平均价1股每手
关于ATAI Life Sciences公司
ATAI Life Sciences NV 是一家临床阶段的生物制药公司，旨在改变精神疾病的治疗方式。 其候选产品包括 COMP360/Psilocybin疗法、PCN-101/R-氯胺酮、RL-007/Compound、DMX-1002/Ibogaine、GRX-917/Deuterated etifoxine、VLS-01/DMT、EMP-01/MDMA 衍生物、RLS -01/Salvinorin A、KUR-101/Deuterated Mitragynine 和 DMX-1001/Noribogaine。该公司在美国和德国两个地区开展业务。
公司介绍
公司代码ATAI
公司名称ATAI Life Sciences
上市日期2021/06/18
发行价格15.00
成立日期2018
CEOMr. Florian Brand
所属市场纳斯达克
员工数量88
年结日12-31
公司地址Krausenstrasse 9-10
城市Berlin
省份柏林
国家德国
邮编10117
电话49-89-2153-9035
董事高管
- 姓名
- 职务
- 年薪
- Srinivas G. Rao, M.D.,PhD
- Co-Chief Executive Officer
- 173.47万
- Florian Brand
- Co-Chief Executive Officer and Managing Director
- 302.73万
- Dr. Sahil Kirpekar, M.D.
- Chief Business Officer
- --
- Anne Nagengast Johnson
- Chief Accounting Officer, Managing Director and Chief Financial Officer
- 117.02万
- Christian Angermayer
- Chairman of the Supervisory Board
- 15.90万
- Michael Auerbach
- Lead Member of the Supervisory Board
- 15.90万
- Dr. Laurent Fischer, M.D.
- Member of the Supervisory Board
- --
- Dr. Raymond Sanchez, M.D.
- Member of the Supervisory Board
- --
- Dr. Amir Kalali,M.D.
- Member of the Supervisory Board
- 14.05万
- Dr. Scott Braunstein, M.D.
- Member of the Supervisory Board
- --
- Andrea Heslin Smiley
- Member of the Supervisory Board
- 15.05万
- Sabrina Martucci Johnson
- Member of the Supervisory Board
- 15.20万
热议
美股
综合热度
股票代码
最新价
涨跌幅
暂无数据